FDA Expands Approval for Johnson & Johnson's Drug Imaavy to Treat Rare Blood Disorder

The U.S. Food and Drug Administration (FDA) has approved the expanded use of Johnson & Johnson's drug, Imaavy, for treating warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older. This makes Imaavy the first treatment cleared for wAIHA, covering individuals previously or currently treated with steroids.